TherapeuticsMD, Inc. (TXMD)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| License revenue | 952 | 393 | 547 | 234 |
| Depreciation, depletion and amortization | - | - | - | 180 |
| Selling, general and administrative | 1,551 | 1,081 | 1,310 | 1,233 |
| Impairment of long-lived assets (note 4) | - | - | - | 1,261 |
| Depreciation & amortization | 96 | 95 | 96 | - |
| Write-off of patents and trademarks | - | 88 | - | - |
| Total operating expenses | 1,647 | 1,264 | 1,406 | 2,674 |
| Loss from operations | -695 | -871 | -859 | -2,440 |
| Financing interest expense | - | - | 3 | 5 |
| Sublease income | 376 | - | - | - |
| Interest expense and other financing costs | 2 | 2 | - | - |
| Miscellaneous income | 866 | 205 | -295 | -1,395 |
| Total other income, net | 1,240 | 203 | 292 | 1,390 |
| Income (loss) from continuing operations before income taxes | 545 | -668 | -567 | -1,050 |
| Income tax benefit | - | -32 | - | - |
| Income (loss) from continuing operations, net of income taxes | 545 | -636 | -567 | -1,050 |
| Income (loss) from discontinued operations, net of income taxes | 6 | -17 | -42 | -40 |
| Net income (loss) | 551 | -653 | -609 | -1,090 |
| Net income (loss) per common share, basic and diluted (in dollars per share) | 0.05 | -0.06 | -0.05 | -0.09 |
| Net loss per common share, diluted (in dollars per share) | 0.05 | -0.06 | -0.05 | -0.09 |
| Weighted average common shares, basic (in shares) | 11,574,000 | 11,552,000 | 11,532,000 | 11,532,000 |
| Weighted average common shares, diluted (in shares) | 11,574,000 | 11,552,000 | 11,532,000 | 11,532,000 |